Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

COMy 2021

Recent Updates

View all
4:46
Does ASCT still have a place in myeloma treatment?
Muzaffar Qazilbash • 12 May 2021
3:06
Exciting therapeutic developments on the horizon for WM
Steven Treon • 6 May 2021
5:07
New approaches to the treatment of elderly myeloma
Meral Beksac • 10 May 2021
3:38
CITE-seq analysis predicts response to CAR-T therapy and bispecifics in myeloma
Paola Neri • 19 Apr 2021

Myeloma

View all
2:06
Pembrolizumab for consolidation in myeloma
Enrique Ocio • 16 Apr 2021
3:24
Novel agents for the management of R/R myeloma
Enrique Ocio • 16 Apr 2021

Waldenström’s Macroglobulinemia

View all
4:07
Challenges associated with Waldenström’s
Jorge Castillo • 16 Apr 2021
3:28
Emerging therapies for WM: acalabrutinib and zanubrutinib
Steven Treon • 6 May 2021

CAR-T

View all
2:18
Moving forward: bringing CAR-T therapy to a frontline setting in myeloma
Thomas Martin • 22 Apr 2021
5:33
CARs & MAbs: broadening the myeloma armamentarium
Niels van de Donk • 29 Apr 2021

Disease biology

View all
2:54
Waldenström’s therapy: what’s on the horizon?
Jorge Castillo • 16 Apr 2021
4:07
Challenges associated with Waldenström’s
Jorge Castillo • 16 Apr 2021

Trial Updates

View all
10:16
Melflufen: current trials and future directions
Paul Richardson • 20 Apr 2021
2:48
Dara-Kd shows efficacy in len-refractory cohort in latest CANDOR reports
Saad Usmani • 17 May 2021

Controversies

View all
2:25
Complementary and alternative medicine in hematologic disease: help or harm?
Mohamad Mohty • 16 Apr 2021
2:00
Treating multiple myeloma resistant to BCMA-targeted therapy
Niels van de Donk • 29 Apr 2021
Visit the Multiple Myeloma Channel for the latest updates from leading experts

The content of VJHemOnc is intended for healthcare professionals